| 摘要 |
The invention relates to a pharmaceutical composition for oral administration, employed in the medical therapy. The pharmaceutical composition for oral administration comprises: (a) the tetrahydro-3-furanyl ester of the 3S[3Rasterix, (1 Rasterix, 2Sasterix)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl] carbamic acid, (b) a water-soluble derivative of tocopherol and (c) a hydrophylic non-aqueous solvent miscible with said water-soluble tocopherol derivative, where the ratio of (a) to (b) ranges from 1 : 0.5 to 1 :10 w/w, (a), (b) and (c) are maintained in a formulated state, as a liquid fluid. The pharmaceutical composition for oral administration may contain (a) the tetrahydro-3-furanyl ester of the 3S[3Rasterix, (1Rasterix, 2Sasterix)]-[3-[[(4-aminophenyl)sulphonyl] (2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid in an amount ranging from 1% to 50% w/w, based on the total weight of the composition, (b) a water-soluble derivative of the tocopherol in an amount ranging from 10% to 60% w/w, in relation to the total weight of the composition and (c) a hydrophylic non-aqueous solvent, miscible with said water-soluble tocopherol derivative, in an amount ranging from 25% to 60% w/w in relation to the total weight of the composition, (a), (b) and (c) being maintained in a formulated state, as a liquid fluid. |
